Response to: Effect of dose reductions on clinical outcomes, or of outcomes on dose reductions?

• R.K. Ismail,
• J. van Breeschoten,
• M.W.J.M. Wouters,
• M. van Dartel,
• S. van der Flier,
• A.K.L. Reyners,
• P. de Graeff,
• A.M.G. Pasmooij,
• A. de Boer,
• K.E. Broekman,
• D.L. Hilarius

Affiliations

R.K. Ismail

Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, Leiden, 2333AA, the Netherlands; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, the Netherlands; Corresponding author. Rijnsburgerweg 10, 2333AA, Leiden, the Netherlands.

J. van Breeschoten

Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, Leiden, 2333AA, the Netherlands; Department of Medical Oncology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan, 1118, Amsterdam, 1081HZ, the Netherlands

M.W.J.M. Wouters

Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, Leiden, 2333AA, the Netherlands; Department of Surgical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066CX, the Netherlands; Department of Biomedical Data Sciences, Leiden University Medical Centre, Albinusdreef 2, Leiden, 2333ZA, the Netherlands

M. van Dartel

Medicines Evaluation Board, Graadt van Roggenweg 500, Utrecht, 3531AH, the Netherlands

S. van der Flier

Co€operatie VGZ U.A, Nieuwe Stationsstraat 12, Arnhem, 6811KS, the Netherlands

A.K.L. Reyners

Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen, 9713, GZ, the Netherlands

P. de Graeff

University of Groningen, University Medical Center Groningen, University Center for Geriatric Medicine, Hanzeplein 1, Groningen, 9700, RB, the Netherlands

A.M.G. Pasmooij

Medicines Evaluation Board, Graadt van Roggenweg 500, Utrecht, 3531AH, the Netherlands

A. de Boer

Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, the Netherlands; Medicines Evaluation Board, Graadt van Roggenweg 500, Utrecht, 3531AH, the Netherlands

K.E. Broekman

Medicines Evaluation Board, Graadt van Roggenweg 500, Utrecht, 3531AH, the Netherlands; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen, 9713, GZ, the Netherlands

D.L. Hilarius

Department of Pharmacy, Rode Kruis Ziekenhuis, Vondellaan 13, Beverwijk, 1942LE, the Netherlands